Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) EBIT Margin: 2012-2024

Historic EBIT Margin for Sunshine Biopharma (SBFM) over the last 11 years, with Dec 2024 value amounting to -16.67%.

  • Sunshine Biopharma's EBIT Margin rose 158.00% to -11.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.35%, marking a year-over-year decrease of 244.00%. This contributed to the annual value of -16.67% for FY2024, which is 320.00% up from last year.
  • As of FY2024, Sunshine Biopharma's EBIT Margin stood at -16.67%, which was up 16.09% from -19.86% recorded in FY2023.
  • In the past 5 years, Sunshine Biopharma's EBIT Margin ranged from a high of -16.67% in FY2024 and a low of -1,068.24% during FY2021.
  • For the 3-year period, Sunshine Biopharma's EBIT Margin averaged around -219.29%, with its median value being -19.86% (2023).
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 223,007bps in 2020, then slumped by 26,040bps in 2021.
  • Yearly analysis of 5 years shows Sunshine Biopharma's EBIT Margin stood at -807.83% in 2020, then slumped by 26,040bps to -1,068.24% in 2021, then surged by 44,690bps to -621.33% in 2022, then soared by 60,147bps to -19.86% in 2023, then skyrocketed by 320bps to -16.67% in 2024.